Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Alliant Energy Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Alliant Energy Corporation trades at $76.76 (market cap $20.06B). The key difference: Alliant Energy Corporation is far larger — about 4.5× ACADIA Pharmaceuticals Inc.'s market cap, and Alliant Energy Corporation pays a 2.69% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | LNT | |
|---|---|---|
Market Cap | $4.49B | $20.06B |
Sector | Health | Utilities |
52-Week High | $28.06 | $78.03 |
52-Week Low | $20.06 | $61.26 |
Enterprise Value | $3.69B | $31.78B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
LNT trades at $77.65, down 0.49% on the day, with a bullish technical signal from moving averages and key resistance at $78. The company reported revenue of $4.36B in 2025 with net income of $810M, and recent quarters show mixed earnings performance against estimates. A $13.4B investment plan supports growth in data center demand and clean energy expansion, while analyst consensus is a Buy with a $75.67 price target.
LNT offers steady utility earnings growth and a dividend yield, but faces risks from rising debt levels and interest expenses. The stock's valuation multiples are above sector averages, requiring continued execution on capital investments to justify premium pricing amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
